Premium
Phase II study of mitomycin‐C, vincristine, and bleomycin in advanced squamous cell carcinoma of the uterine cervix
Author(s) -
Baker Laurence H.,
Opipari Michael I.,
Izbicki Ronald M.
Publication year - 1976
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197612)38:6<2222::aid-cncr2820380605>3.0.co;2-r
Subject(s) - medicine , vincristine , leukopenia , mitomycin c , bleomycin , chemotherapy , rash , bolus (digestion) , gastroenterology , cervix , toxicity , surgery , urology , cyclophosphamide , cancer
Utilizing the stathmokinetic principle of timed vincristine and bleomycin, we combined these two agents with Mitomycin‐C. The dose schedule included vincristine 0.5 mg/m 2 intravenously (i.v.) beginning on day 1 and repeated twice weekly for 12 weeks; each injection was followed in 6–12 hours by bleomycin 6 mg/m 2 for 12 weeks. Mitomycin‐C was administered as a 20 mg/m 2 bolus beginning on day 2 and repeated at 6‐week intervals. Thirty patients were entered into this study, 27 were fully available for response. Thirteen patients (48%) met criteria of response (greater than 50% reduction in volume of measurable tumor). Significant myelosuppression resulted from this therapy. Median leukopenia nadir was 3.8 × 10 3 cells/mm 3 and median thrombocytopenia nadir was 116 × 10 3 cells/mm 3 . Additional toxic reactions included anemia, lassitude, anorexia, peripheral neuropathy fever, and skin rash. Despite significant, but manageable, toxicity, this combination appears to represent an improvement in the chemotherapy of a traditionally refractory solid tumor.